Sarepta Therapeutics (SRPT)
(Real Time Quote from BATS)
$141.78 USD
-2.23 (-1.55%)
Updated Aug 2, 2024 10:34 AM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
SRPT 141.78 -2.23(-1.55%)
Will SRPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRPT
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
5 Biotech Stocks to Bet On Bright Industry Prospects
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to Trade
What Makes Sarepta Therapeutics (SRPT) a Strong Momentum Stock: Buy Now?
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
Other News for SRPT
REGENXBIO releases new data on DMD drug ahead of earnings
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PepGen downgraded to Neutral at BofA after DMD data reported
Sanofi unit Genzyme sues Sarepta alleging patent infringement in Duchenne drug
PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments